VENLAFAXINE VIATRIS GENERIQUES L.P. 75 mg, extended-release capsule 30 capsules
Active ingredients: Venlafaxine hydrochloride, Venlafaxine
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VENLAFAXINE VIATRIS GENERIQUES L.P. 75 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 30 gélule(s)
- Marketing authorisation holder
- VIATRIS UP
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 26 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69018164CIP73465679CIP133400934656798Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE VENLAFAXINEgélule | 84,850 mg · une gélule | SA |
| VENLAFAXINEgélule | 75 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.